Skip to main content
. 2013 Oct 22;8(10):e77795. doi: 10.1371/journal.pone.0077795

Figure 5. Experimental therapies with WP1066 in OVA-challenged chronic asthmatic mice.

Figure 5

(A) OVA-challenge was performed in BALB/c mice as described [28]. WP1066 was administered by intraperitoneal injection at doses of 40mg/kg 1h before the OVA-challenge. Airway resistance was measured using increasing concentration of methacholine and assessed using the flexiVent system. Results are expressed as the mean of experiments done in triplicate ± the standard error of the mean (SEM) (* p<0.05, **p>0.05 vs control). (B) TSLP, p16, p21, Ki-67, α-SMA and collagen I protein expressions were analyzed, 200×. (C) Bimodal H score distribution of TSLP, p16, p21, Ki67, α-SMA and collagen I immunoperoxidase reactions are presented.